Free Trial
NASDAQ:OBIO

Orchestra BioMed (OBIO) Stock Price, News & Analysis

Orchestra BioMed logo
$6.23
+0.77 (+14.10%)
(As of 11/5/2024 ET)

About Orchestra BioMed Stock (NASDAQ:OBIO)

Key Stats

Today's Range
$5.41
$6.24
50-Day Range
$4.61
$6.70
52-Week Range
$4.22
$11.69
Volume
67,050 shs
Average Volume
76,347 shs
Market Capitalization
$235.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.75
Consensus Rating
Buy

Company Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Orchestra BioMed Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
44th Percentile Overall Score

OBIO MarketRank™: 

Orchestra BioMed scored higher than 44% of companies evaluated by MarketBeat, and ranked 641st out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Orchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Orchestra BioMed has only been the subject of 1 research reports in the past 90 days.

  • Read more about Orchestra BioMed's stock forecast and price target.
  • Earnings Growth

    Earnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.67) to ($1.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Orchestra BioMed is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Orchestra BioMed is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Orchestra BioMed has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Orchestra BioMed's valuation and earnings.
  • Percentage of Shares Shorted

    3.18% of the float of Orchestra BioMed has been sold short.
  • Short Interest Ratio / Days to Cover

    Orchestra BioMed has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Orchestra BioMed has recently decreased by 9.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Orchestra BioMed does not currently pay a dividend.

  • Dividend Growth

    Orchestra BioMed does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.18% of the float of Orchestra BioMed has been sold short.
  • Short Interest Ratio / Days to Cover

    Orchestra BioMed has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Orchestra BioMed has recently decreased by 9.41%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Orchestra BioMed has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Orchestra BioMed insiders have sold 415.62% more of their company's stock than they have bought. Specifically, they have bought $26,875.00 in company stock and sold $138,573.00 in company stock.

  • Percentage Held by Insiders

    Only 6.70% of the stock of Orchestra BioMed is held by insiders.

  • Percentage Held by Institutions

    53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Orchestra BioMed's insider trading history.
Receive OBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter.

OBIO Stock News Headlines

MDT Aug 2024 81.000 put
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
MDT Aug 2024 87.000 call
See More Headlines

OBIO Stock Analysis - Frequently Asked Questions

Orchestra BioMed's stock was trading at $9.13 at the beginning of 2024. Since then, OBIO stock has decreased by 31.8% and is now trading at $6.23.
View the best growth stocks for 2024 here
.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.04. The firm had revenue of $0.78 million for the quarter, compared to the consensus estimate of $1.04 million. Orchestra BioMed had a negative net margin of 2,673.26% and a negative trailing twelve-month return on equity of 89.28%.

Top institutional investors of Orchestra BioMed include ABLE Financial Group LLC (0.04%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Darren Sherman, David P Hochman, William Reed Little and Eric S Fain.
View institutional ownership trends
.

Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchestra BioMed investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/12/2024
Today
11/05/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:OBIO
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.75
High Stock Price Target
$20.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+152.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-49,120,000.00
Net Margins
-2,673.26%
Pretax Margin
-2,673.26%

Debt

Sales & Book Value

Annual Sales
$2.76 million
Book Value
$1.90 per share

Miscellaneous

Free Float
35,291,000
Market Cap
$235.68 million
Optionable
Not Optionable
Beta
0.42
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:OBIO) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners